en · de · es · pt
melanotan-2-notes.peptides8425.com › Topic › Melanotan-2 Identity And Regulatory Status — Practical Notes

Melanotan-2 Identity And Regulatory Status — Practical Notes

By Editorial Desk · published 2025-11-26 · last reviewed 2026-01-04 · Topic

This is a working overview of MC1R, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-01-04 and is reviewed periodically as new material appears.

Melanotan-2 Identity And Regulatory Status

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II Background and Mechanism

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalogue of alpha-melanocyte-stimulating hormone
Common synonymsMT-II; melanotan 2No internationally accepted non-proprietary name
Typical presentationLyophilised powder in a sealed vialOften supplied alongside a separate diluent
Regulatory statusUnapproved therapeutic substanceCustoms seizure reported in several jurisdictions
Reported route in useSubcutaneous injectionSelf-administered outside clinical settings

Supporting material

== Mechanical properties == Graphene aerogels exhibit enhanced mechanical properties as a result of their structure and morphology. Graphene aerogels have a Young's modulus on the order of 50 MPa. They can be compressed elastically to strain values >50%. The stiffness and compressibility of graphene aerogels can be attributed in part to the strong sp2 bonding of graphene and the π-π interaction between carbon sheets. In graphene aerogels, the π-π interaction can greatly enhance stiffness due to the highly curved and folded regions of graphene as observed through transmission electron microscopy images. The mechanical properties of graphene aerogel have been shown to depend on the microstructure and thus varies across studies. The role that microstructure plays in the mechanical properties depends on several factors. Computational simulations show that graphene walls bend when a tensile or compressive stress is applied. The resulting stress distribution from the bending of the graphene walls is isotropic and can contribute to the high yield stress observed. The density of the aerogel can also significantly affect the properties observed. The normalized Young's modulus is shown computationally to follow a power-law distribution governed by the equation E/Es = (ρ/ρs)m, where E is the Young's modulus.

The Turkish and Persian people were the first to cultivate tulips. While the cultivation of tulips in Iranian gardens dates back to the 10th century, the westward expansion of diverse tulip varieties into Asia Minor occurred most significantly under the Seljuk dynasty. The Persian poet Omar Khayyam's 11th-century poetry frequently featured the tulip as a symbol of ideal feminine beauty. Early cultivars must have emerged from hybridisation in gardens from wild collected plants, which were then favoured, possibly due to flower size or growth vigour. The tulip is not mentioned by any writer from antiquity, therefore it seems probable that tulips were introduced into Anatolia only with the advance of the Seljuks. In the Ottoman Empire, numerous types of tulips were cultivated and bred, and today, 14 species can still be found in Turkey. Tulips are mentioned by the 13th century Persian sufi mystic Jalāl ad-Dīn Rûmi. Species of tulips in Turkey typically come in red, less commonly in white or yellow. The Ottoman Turks had discovered that these wild tulips were great changelings, freely hybridising (though it takes 7 years to show colour) but also subject to mutations that produced spontaneous changes in form and colour. A paper by Arthur Baker reports that in 1574, Sultan Selim II ordered the Kadi of A'azāz in Syria to send him 50,000 tulip bulbs. However, John Harvey points out several problems with this source, and there is also the possibility that tulips and hyacinth (sümbüll), originally Indian spikenard (Nardostachys jatamansi) have been confused.

== History == The uterine-contracting properties of the principle that would later be named oxytocin were discovered by British pharmacologist Henry Hallett Dale in 1906, and its milk ejection property was described by Ott and Scott in 1910 and by Schafer and Mackenzie in 1911. In 1909 the first clinical use of oxytocin was performed by William Blair-Bell to induce childbirth in patients with complications. By the 1920s, oxytocin and vasopressin had been isolated from pituitary tissue and given their current names. Oxytocin's molecular structure was determined in 1952. In the early 1950s, American biochemist Vincent du Vigneaud found that oxytocin is made up of nine amino acids. He identified its amino acid sequence, the first polypeptide hormone to be sequenced. In 1953, du Vigneaud carried out the synthesis of oxytocin, the first polypeptide hormone to be synthesized. Du Vigneaud was awarded the Nobel Prize in Chemistry in 1955 for his work. Further work on different synthetic routes for oxytocin, as well as the preparation of analogues of the hormone (e.g. 4-deamido-oxytocin) was performed in the following decade by Iphigenia Photaki.

Sources: en.wikipedia.org

Related pages on this site

Notes from published material

Scleral lenses are sometimes prescribed for cases of advanced or very irregular keratoconus; these lenses cover a greater proportion of the surface of the eye and hence can offer improved stability. Easier handling can find favor with people with reduced dexterity, such as the elderly.

Ribonucleoprotein Networks Analyzed by Mutational Profiling (RNP-MaP) is a strategy for probing RNA-protein networks and protein binding sites at a nucleotide resolution. Information about RNP assembly and function can facilitate a better understanding of biological mechanisms. RNP-MaP uses NHS-diazirine (SDA), a hetero-bifunctional crosslinker, to freeze RNA-bound proteins in place. Once the RNA-protein crosslinks are formed, MaP reverse transcription is then conducted to reversely transcribe the protein-bound RNAs as well as introduce mutations at the site of RNA-protein crosslinks. Sequencing results of the cDNAs reveal information about both protein-RNA interaction networks and protein binding sites.

Mary Osborn (born in 1940) is a L'Oréal-UNESCO Women in Science Award-winning English cell biologist who, until she stopped running an active laboratory in 2005, was on the scientific staff at the Max Planck Institute for Biophysical Chemistry, Göttingen, Germany. Osborn established two techniques frequently used by cell biologists. She pioneered both molecular weight determination of proteins using SDS PAGE and immunofluorescence microscopy. Osborn also used the immunofluorescence microscopy method to work out the details of the eukaryotic cytoskeleton. Small differences in the intermediate filament constituents helped her distinguish differentiated cells from each other. She also found intermediate filament immunofluorescence differences between normal versus cancer cells. Mary Osborn has been a prominent spokesperson for women in science.

Sources: en.wikipedia.org

Further detail

The periodontal ligament, commonly abbreviated as the PDL, are a group of specialized connective tissue fibers that essentially attach a tooth to the alveolar bone within which they sit. It inserts into root cementum on one side and onto alveolar bone on the other.

The protein in cow's milk is approximately 20% whey and 80% casein. The protein in human milk is approximately 60% whey and 40% casein. The protein fraction in whey constitutes approximately 10% of the total dry solids in whey. This protein is typically a mixture of beta-lactoglobulin (~65%), alpha-lactalbumin (~25%), bovine serum albumin (~8%) (see also serum albumin), and immunoglobulins. The third largest fragment of whey protein isolate derived from sweet whey is glycomacropeptide or GMP. However, GMP lacks the secondary structure necessary for it to be classified as a protein and is considered a long amino acid chain. These peptides are all soluble in water in their native forms.

Human Timeline (Interactive) – Smithsonian, National Museum of Natural History (August 2016). Donsmaps: a vast repository of Paleolithic resources Interactive Timeline Simile/Timemap index of Eurasian sites

The friction factor fD is not a constant: it depends on such things as the characteristics of the pipe (diameter D and roughness height ε), the characteristics of the fluid (its kinematic viscosity ν [nu]), and the velocity of the fluid flow ⟨v⟩. It has been measured to high accuracy within certain flow regimes and may be evaluated by the use of various empirical relations, or it may be read from published charts. These charts are often referred to as Moody diagrams, after L. F. Moody, and hence the factor itself is sometimes erroneously called the Moody friction factor. It is also sometimes called the Blasius friction factor, after the approximate formula he proposed. Figure 1 shows the value of fD as measured by experimenters for many different fluids, over a wide range of Reynolds numbers, and for pipes of various roughness heights. There are three broad regimes of fluid flow encountered in these data: laminar, critical, and turbulent.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Where did melanotan II originate?

It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.

Why is purity a concern for unapproved peptides?

Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.

What class of compound is melanotan II?

It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.

Network